192 related articles for article (PubMed ID: 27001273)
1. Kappa opioid receptor antagonism and chronic antidepressant treatment have beneficial activities on social interactions and grooming deficits during heroin abstinence.
Lalanne L; Ayranci G; Filliol D; Gavériaux-Ruff C; Befort K; Kieffer BL; Lutz PE
Addict Biol; 2017 Jul; 22(4):1010-1021. PubMed ID: 27001273
[TBL] [Abstract][Full Text] [Related]
2. Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence.
Lutz PE; Ayranci G; Chu-Sin-Chung P; Matifas A; Koebel P; Filliol D; Befort K; Ouagazzal AM; Kieffer BL
Neuropsychopharmacology; 2014 Oct; 39(11):2694-705. PubMed ID: 24874714
[TBL] [Abstract][Full Text] [Related]
3. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.
Rothman RB; Gorelick DA; Heishman SJ; Eichmiller PR; Hill BH; Norbeck J; Liberto JG
J Subst Abuse Treat; 2000 Apr; 18(3):277-81. PubMed ID: 10742642
[TBL] [Abstract][Full Text] [Related]
4. Dissociation of heroin-induced emotional dysfunction from psychomotor activation and physical dependence among inbred mouse strains.
Ayranci G; Befort K; Lalanne L; Kieffer BL; Lutz PE
Psychopharmacology (Berl); 2015 Jun; 232(11):1957-71. PubMed ID: 25482274
[TBL] [Abstract][Full Text] [Related]
5. Hostility in heroin abusers subtypes: fluoxetine and naltrexone treatment.
Gerra G; Fertonani G; Zaimovic A; Rota-Graziosi I; Avanzini P; Caccavari R; Delsignore R; Lucchini A
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Dec; 19(8):1225-37. PubMed ID: 8868205
[TBL] [Abstract][Full Text] [Related]
6. Amygdala dynorphin/κ opioid receptor system modulates depressive-like behavior in mice following chronic social defeat stress.
Zan GY; Sun X; Wang YJ; Liu R; Wang CY; Du WJ; Guo LB; Chai JR; Li QL; Liu ZQ; Liu JG
Acta Pharmacol Sin; 2022 Mar; 43(3):577-587. PubMed ID: 34035484
[TBL] [Abstract][Full Text] [Related]
7. A role for kappa-, but not mu-opioid, receptor activation in acute food deprivation-induced reinstatement of heroin seeking in rats.
Sedki F; Eigenmann K; Gelinas J; Schouela N; Courchesne S; Shalev U
Addict Biol; 2015 May; 20(3):423-32. PubMed ID: 24725195
[TBL] [Abstract][Full Text] [Related]
8. Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine.
Browne CA; Falcon E; Robinson SA; Berton O; Lucki I
Int J Neuropsychopharmacol; 2018 Feb; 21(2):164-174. PubMed ID: 29020387
[TBL] [Abstract][Full Text] [Related]
9. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.
Krupitsky EM; Zvartau EE; Masalov DV; Tsoy MV; Burakov AM; Egorova VY; Didenko TY; Romanova TN; Ivanova EB; Bespalov AY; Verbitskaya EV; Neznanov NG; Grinenko AY; O'Brien CP; Woody GE
J Subst Abuse Treat; 2006 Dec; 31(4):319-28. PubMed ID: 17084785
[TBL] [Abstract][Full Text] [Related]
10. Two short-acting kappa opioid receptor antagonists (zyklophin and LY2444296) exhibited different behavioral effects from the long-acting antagonist norbinaltorphimine in mouse anxiety tests.
Huang P; Yakovleva T; Aldrich JV; Tunis J; Parry C; Liu-Chen LY
Neurosci Lett; 2016 Feb; 615():15-20. PubMed ID: 26780565
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention].
Grinenko AIa; Krupitskiĭ EM; Zvartau EE
Vestn Ross Akad Med Nauk; 2003; (10):54-6. PubMed ID: 14598513
[TBL] [Abstract][Full Text] [Related]
12. Impact of Pharmacological Manipulation of the
Butelman ER; McElroy BD; Prisinzano TE; Kreek MJ
J Pharmacol Exp Ther; 2019 Jul; 370(1):1-8. PubMed ID: 30975792
[TBL] [Abstract][Full Text] [Related]
13. Extended-release naltrexone modulates brain response to drug cues in abstinent heroin-dependent patients.
Langleben DD; Ruparel K; Elman I; Loughead JW; Busch EL; Cornish J; Lynch KG; Nuwayser ES; Childress AR; O'Brien CP
Addict Biol; 2014 Mar; 19(2):262-71. PubMed ID: 22747521
[TBL] [Abstract][Full Text] [Related]
14. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
Solinas M; Goldberg SR
Psychopharmacology (Berl); 2005 Jun; 179(4):804-12. PubMed ID: 15619107
[TBL] [Abstract][Full Text] [Related]
15. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies.
Zhang H; Shi YG; Woods JH; Watson SJ; Ko MC
Eur J Pharmacol; 2007 Sep; 570(1-3):89-96. PubMed ID: 17601558
[TBL] [Abstract][Full Text] [Related]
16. Effects of a post-shock injection of the kappa opioid receptor antagonist norbinaltorphimine (norBNI) on fear and anxiety in rats.
Rogala B; Li Y; Li S; Chen X; Kirouac GJ
PLoS One; 2012; 7(11):e49669. PubMed ID: 23166745
[TBL] [Abstract][Full Text] [Related]
17. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses.
McLaughlin JP; Marton-Popovici M; Chavkin C
J Neurosci; 2003 Jul; 23(13):5674-83. PubMed ID: 12843270
[TBL] [Abstract][Full Text] [Related]
18. 3-Methoxynaltrexone is not a selective antagonist for the acute psychomotor stimulating effects of heroin and 6-monoacetylmorphine in mice.
Eriksen GS; Andersen JM; Boix F; Mørland J
Pharmacol Biochem Behav; 2014 Jul; 122():82-8. PubMed ID: 24699386
[TBL] [Abstract][Full Text] [Related]
19. Treatment of cocaine craving with as-needed nalmefene, a partial κ opioid receptor agonist: first clinical experience.
Grosshans M; Mutschler J; Kiefer F
Int Clin Psychopharmacol; 2015 Jul; 30(4):237-8. PubMed ID: 25647453
[TBL] [Abstract][Full Text] [Related]
20. Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine.
Goeldner C; Lutz PE; Darcq E; Halter T; Clesse D; Ouagazzal AM; Kieffer BL
Biol Psychiatry; 2011 Feb; 69(3):236-44. PubMed ID: 20947067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
